Swiss dental firm unveils drill-free cavity treatment at J.P. Morgan event

Swiss healthcare company vVARDIS presented its drill-free early cavity treatment, Curodont, at the 2026 J.P. Morgan Healthcare Conference and reported that more than 2 million teeth have been treated in the U.S. since its launch two years ago.

vVARDIS, a Swiss healthcare company founded by dentists Drs. Haley and Goly Abivardi, presented its non-invasive early cavity treatment, Curodont, at the 2026 J.P. Morgan Healthcare Conference. The company described Curodont as a drill-free option that uses a biomimetic formulation intended to work with minerals in saliva to restore tooth structure. vVARDIS reported rapid U.S. uptake since the product's launch two years ago and framed the presentation within a wider public health awareness push called "Save Teeth Save Lives." The article is based on a company press release and was generated with AI support and editorial review. Key facts: - vVARDIS reported that over 2 million teeth have been treated with Curodont in the U.S. within 24 months of its market introduction. - The company said Curodont is available in nearly 12 percent of U.S. dental offices. - The treatment is described as drill-free and uses a proprietary biomimetic formulation that interacts with saliva minerals, according to the company's presentation. - vVARDIS announced $85 million in funding from OrbiMed and an expanded partnership with Henry Schein. - The company noted adoption by dental practices including large dental service organizations and said Dental Advisor named vVARDIS its 2026 Innovative Company of the Year. Summary: The presentation highlighted vVARDIS's reported U.S. uptake, partnerships, and a public awareness campaign that frames cavities as a widespread health concern. Undetermined at this time.